HIV and ID Observations

August 9th, 2012

New PrEP “Guidance” Released by CDC

The CDC issued its second “Interim Guidance” on the use of tenofovir/FTC as pre-exposure prophylaxis for prevention of HIV, this time for prevention of HIV in heterosexually active adults. The rationale? Since January 2011, data from studies of PrEP among heterosexual men and women have become available, and on July 16, 2012, the Food and Drug […]

---

August 8th, 2012

Must-Read Piece: “Imagine a World Without AIDS”

With all the hoopla at last month’s International AIDS Conference about ending AIDS and curing AIDS and bringing us an AIDS-free generation, there was plenty of ink spilled on the topic. Ironically, the attention the meeting received was inversely proportional to its scientific content, which was actually fairly light on a content-per-day scale. The meeting probably […]

---

August 1st, 2012

Really Rapid Review — 2012 International AIDS Conference, Washington, DC

Last week’s International AIDS Conference in Washington got plenty of media attention, mostly because it was the first time in umpteen years that it was held in the United States, the delay between meetings due to our absurd (and now repealed) immigration laws regarding HIV. (Quick trivia question — where was the conference supposed to be […]

---

July 29th, 2012

A Quick Note to Time Magazine

Dear Time Magazine, Thanks for the recent coverage of HIV treatment. One small suggestion: in the future, try to find some some stock photos of HIV medications that are somewhat more up-to-date than, um, 1997, which is what you chose here and here. In our field, seeing these original AZT, ddC, and nelfinavir tablets is kind of like seeing […]

---

July 26th, 2012

Pigs are Flying: Written Consent No Longer Needed for an HIV Test in Massachusetts

Let the record show that as of July 26, 2012, a person in Massachusetts can legally get an HIV test without signing a written consent. Hooray. There, that wasn’t so hard, was it?

---

July 25th, 2012

AIDS Quilt, the Early 1990s, and Sadness

The early 1990s has potentially many associations — the break-up of the Soviet Union, the first Gulf War, the World Trade Center and Oklahoma City bombings, The Lion King, Forest Gump, The Fresh Prince of Bel-Air, “Smells Like Teen Spirit”, and the cancellation of the baseball season, to name a few. But we HIV/ID specialists will always […]

---

July 23rd, 2012

IAS-USA HIV Guidelines Updated

With the International AIDS Conference in Washington just starting, the International Antiviral (ahem) Society-USA has revised its HIV treatment guidelines, updating the 2010 version. As has been the case for several years now, it’s published in JAMA and also available on the IAS-USA web site. It’s a well written, evidence-driven summary of the current state of […]

---

July 1st, 2012

“HAART Era” Now Longer Than “Pre-HAART Era” — Can We Officially Retire “HAART”?

As I’ve shared before, I’m no fan of the term “HAART” and do everything I can to stop people from using it. (I’m a fun guy to have at parties.) I’m returning to this pet peeve of mine because I realized recently that we’ve passed a milestone of sorts: Period of no effective HIV treatment, 15 years (1981-1996) […]

---

June 29th, 2012

HIV Testing Roundup, and a Brief Rant

I’ve written so many times about HIV testing that a complete list of the headlines fills two full web pages. But since the last entry on the topic was more than a month ago, one might think I’ve lost interest in the topic. Never! Three items on the HIV Testing radar, two national, one local. First, for a classic […]

---

June 20th, 2012

Abacavir Becomes the Latest Generic Antiretroviral Agent

Hot on the heels of generic nevirapine comes generic abacavir: On June 18, 2012, FDA granted approval for a generic formulation of abacavir tablets, 300 mg, manufactured by Mylan Pharmaceuticals, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to the […]

---